Synaptogenix raises $5.0M via Series C preferred stock and warrants, convertible/exercisable at $4.00/share

TAO Synergies Inc.

Gross proceeds of $5.0M from sale of 5,000 shares of Series C convertible preferred stock (stated value $1,000) and warrants.
Series C convertible at $4.00/share, pays 5% quarterly cash dividend; warrants exercisable at $4.00 for 5 years.
Closing expected September 12, 2024; net proceeds for general corporate purposes, including potential R&D or acquisitions.
CEO Alan Tuchman noted support from existing investors and aims to be strategic for growth and shareholder value.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.